10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
2026-10-05 08:26
•Keith Speights •The Motley Fool
•••• ••••••••• Axe Cap view
Argenx Bulls Eye Strong Upside But Watch Clinical Risks
Wall Street analysts see substantial upside in Argenx’s stock, driven by solid biotech growth, yet key risks remain.
Argenx’s strong 60% revenue growth led by its Vyvgart franchise has caught Wall Street’s attention, with most analysts calling it a buy and price targets near $1,200 or higher. The company’s pipeline targeting autoimmune diseases adds promise, but it’s important to remember biotech stocks often face binary risks—trial results can make or break valuations quickly. For South African investors, direct exposure isn’t possible on the JSE, so monitoring USD/ZAR currency movements will be key, as a weaker rand could increase the local cost of investing offshore. Companies like Naspers or Prosus occasionally reflect global tech and biotech trends but don’t have direct exposure here. If clinical setbacks appear, the hype could quickly reverse. Given the strong consensus but inherent biotech risk, a cautious approach is warranted. this is just our opinion and not financial advice
Wait to initiate a small position in Argenx via ADRs or US ETFs with biotech exposure, while watching USD/ZAR. Trim or avoid until trial data is clearer.
- ARGX
- USD/ZAR
- Clinical trial failures
- Rand volatility increasing local investment costs
6/10
Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.
Our take is based on reporting first published by The Motley Fool.